Company / PP&E (Net)
Monte Rosa Therapeutics, Inc. PP&E (Net) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$29.5M
FY2024
5-year range
$4.6M / $33.8M
FY2020-FY2024
Trend
-12.8%
vs FY2023
Sector context
#72 of 193
Health Care
What the data says
At $29M, Monte Rosa Therapeutics, Inc.'s pp&e (net) ranks #72 of 193 in the Health Care sector. Improved from $27M to $29M over the past 2 years.
Based on SEC 10-K filings.
$29M in FY2024 with a 3-year CAGR of +33.7%.
Improved from $27M to $29M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +33.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#72 of 193 in Health CareTop 37% of 193This company $29.5M Sector average $777.6M
▼
-96.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +33.7%, indicating consistent growth.
- In FY2024, pp&e (net) decreased 12.8% year-over-year.
- Ranks #72 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $29.5M | -12.8% |
| FY2023 | $33.8M | +24.8% |
| FY2022 | $27.1M | +119.7% |
| FY2021 | $12.3M | +166.6% |
| FY2020 | $4.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026